Photodynamic therapy (PDT) is a clinically approved method for tumor ablation. PDT includes two elements: (1) a PDT drug (also known as a photosensitizer (PS)) and (2) light for irradiating the PS. During treatment, the photoexcited PS produces reactive oxygen species (ROS) to damage and kill cells in the vicinity of the PS. Generation of excessive ROS in tissue leads to cell death and tumor destruction. Most current PS molecules (e.g., porphyrin, chlorin, porphycene, etc.) are macrocyclic compounds which suffer from poor water solubility, with a tendency to aggregate via π-π stacking in polar media such as aqueous solutions. This results in reduced effective concentrations and renders the PS molecules photodynamically inactive or less effective when administered to the tissues. Zinc (II) phthalocyanine (ZnPC), a derivative of porphyrin, is a promising PS due to its high ROS quantum yield, also suffers from the above limitations when administered to the body. Although there are several synthetic approaches (including the addition of charged, water-soluble substituents) to render the ZnPC more stable in aqueous media, none of these have satisfactorily solved the problem without the further addition of surfactants or organic solvents (which can be toxic). Further, the introduction of charged substituents reduces the ability of ZnPC to interface with cellular structures such as the plasma membrane. Additional issues are the lack of subcellular specificity of ZnPC once internalized into cells which reduces its therapeutic efficacy. Recent developments of nanoparticle-based formulation of PS molecules have addressed some of the solubility/delivery issues for ZnPC. However, the self-aggregation even inside the NPs and specific delivery to the subcellular location remains challenging. Another limitation of currently employed PS molecules is their rather modest two photon absorption (TPA) which limits their use in deeper tissue applications
A need exists for improved photosensitizers for photodynamic therapy.
Described herein is a hybrid liquid crystal nanoparticle (LCNP)-based delivery system for the encapsulation and targeted delivery of Zinc (II) phthalocyanine (ZnPC) to the plasma membrane bilayer of living cells. The formulation comprises LCNPs that are loaded in their hydrophobic core with perylene (PY) and ZnPC. In embodiments, the LCNP surface is functionalized with Poly(ethylene glycol)-cholesterol conjugates (PEG-Chol) and/or another material enabling targeting the particle to the cellular membrane. Targeting the LCNPs to the plasma membrane with the PEG-Chol moiety improves cell killing via reactive oxygen species (ROS) generation as it allows for the localized ROS-mediated peroxidation of lipids in the membrane bilayer.
Co-loading the PY and ZnPC into the LCNP achieves the following objectives: (1) optically exciting the ZnPC via fluorescence resonance energy transfer (FRET) by using the photoexcited PY as the energy donor, (2) preventing the self-aggregation of ZnPC inside the particle core, (3) allowing tracking/imaging of the particles or labelled tissue using fluorescence-based imaging, and (4) improving the two photon absorption (TPA) of the ZnPC by using the PY dye (which has a large TPA) as energy donor.
Definitions
Before describing the present invention in detail, it is to be understood that the terminology used in the specification is for the purpose of describing particular embodiments, and is not necessarily intended to be limiting. Although many methods, structures and materials similar, modified, or equivalent to those described herein can be used in the practice of the present invention without undue experimentation, the preferred methods, structures and materials are described herein. In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below.
As used herein, the singular forms “a”, “an,” and “the” do not preclude plural referents, unless the content clearly dictates otherwise.
As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items.
As used herein, the term “about” when used in conjunction with a stated numerical value or range denotes somewhat more or somewhat less than the stated value or range, to within a range of ±10% of that stated.
Overview
A multifunctional liquid crystal nanoparticle (LCNP) can be loaded with a dye (such as perylene (PY)) and a PDT drug (such as Zinc (II) phthalocyanine, termed ZnPC) as an energy donor and acceptor, respectively, for PDT treatment. This hybrid LCNP includes (1) a hydrophobic core where the hydrophobic molecules PY and ZnPC are incorporated during synthesis and (2) a carboxylate functionalized surface where a ligand (PEGylated-cholesterol, PEG-Chol) is covalently conjugated to mediate attachment of the LCNP to the plasma membrane of cells. Tight packing of the PY and ZnPC in the LCNP core allows the NP to efficiently generate reactive oxygen species (ROS) via FRET from PY to ZnPC, while PEG-Chol facilitates the close association of the LCNP with the plasma membrane. FRET excitation of the PY-ZnPC pair surprisingly generates significantly greater reactive oxygen species ROS (3.5-fold) in cells labeled with the PDT LCNPs compared to when the ZnPC is excited directly, thus making it a novel and more efficient NP-based PDT treatment.
As detailed below, the LCNPs were delivered to the plasma membrane of living cancer cells that are subjected to PDT treatment with direct (638 nm) and FRET (532 nm) excitation of the ZnPC PDT moiety for 30 min. Both cellular proliferation and migration were significantly reduced when cells were treated with PY-ZnPC-LCNP via FRET excitation of ZnPC. FRET excitation of the ZnPC reduces cellular viability 83% compared to a reduction in cellular viability of only 95% when excited in direct excitation mode.
Additional details regarding the preparation and modification of LCNPs can be found in “Hybrid Liquid Crystal Nanocarriers for Enhanced Zinc Phthalocyanine-Mediated Photodynamic Therapy” by Okhil K. Nag et al., Bioconjugate Chemistry Article ASAP online publication DOI: 10.102/acs.bioconjchem.8b00374 as well as the first group of references at the end of this specification, all of which are incorporated herein by reference for the purposes of teaching the preparation and modification of LCNPs.
The bare LCNPs were further surface modified with PEG2000-Chol via EDC coupling.
Successful encapsulation of ZnPC in LCNPs and co-encapsulation of PY and ZnPC in the hybrid LCNP were confirmed by UV-vis spectroscopy (
ROS generation efficiency of the LCNPs was studied with a fluorescence probe that shows an increase in fluorescence emission upon generation of ROS. As show in
Fluorescence imaging was used to confirm the successful labeling of the plasma membrane of cells with the LCNPs-PEG-Chol. As evidenced by the fluorescence micrographs in
Given efficient ROS generation and the controlled membrane-specific delivery of PY-ZnPC-LCNPs, the ability the LCNPs to modulate cellular migration/proliferation after irradiation with light was examined. For this, a scratch wound assay was performed after labeling the cells with LCNPs, exposing the labeled cells to excitation light, and then culturing in standard incubation condition for 48 h (
To further confirm these results, cells treated with PY-ZnPC-LCNPs (excited at 532 nm) were stained with trypan blue (a dye that is excluded by viable cells but taken up readily by non-viable cells). Compared to control, the cells treated with PY-ZnPC-LCNPs (excited at 532 nm) showed robust (nearly 100%) trypan blue staining, indicative of efficient cell killing by the LCNPs (
Finally, to understand the mechanism of the phototoxicity responses, the morphological change of the cell in early stages (2 h window) after the PDT treatment was studied by imaging cytosolic actin microfilaments and the nucleus. As shown in
Potential uses of the invention include the use and sale of the material for cancer treatment without the need for invasive surgery for removing tumor. Other applications include dermatology (acne), ophthalmology (age-related macular degeneration), urology (bladder cancer), gastroenterology (stomach and esophageal cancer), and respiratory medicine (lung cancer). These materials also could find use in fluorescence image-based diagnosis of the tumor status/progression after treatment.
The LCNP could easily serve as host to other dye donor-acceptor pairs; conceivably increasing the water solubility of the dyes in the context of the LCNP carrier.
The surface of the LCNP can be decorated or conjugated with other biologicals (antibodies, proteins, peptides, small molecules, drugs) to facilitate targeting to specific cell types or subcellular structures.
Advantages
Use of the LCNP-PEG-Chol carrier (hydrophilic surface/hydrophobic core) as a host for the water-insoluble ZnPC provides water solubility and targeted (cell membrane) delivery of the ZnPC. This significantly increases the efficacy of the ZnPC PS moiety.
The ordered, crosslinked hydrophobic LCNP core and co-encapsulation of PY/ZnPC reduce the self-aggregation of the ZnPC, which minimizes its unfavorable optical quenching for PDT application.
The excitation of the ZnPC in a FRET configuration using the PY dye as the FRET energy donor facilitates significantly higher emission efficiency and ROS generation, a non-obvious outcome.
The bright emission profile of PY in LCNP facilitates the optical tracking of PY-ZnPC-LCNP during and after the PDT. Therefore, this preparation enables its eventual use in theranostic (combined diagnostic and therapeutic) applications.
The large two photon absorption (TPA) of the PY moiety (coupled with its ability to serve as a highly efficient FRET donor to the ZnPC acceptor) allows efficient excitation of the ZnPC using longer wavelength light that has higher tissue penetration. The ZnPC alone has minimal TPA, so the PY facilitates use of ZnPC in a two photon mode.
Concluding Remarks
All documents mentioned herein are hereby incorporated by reference for the purpose of disclosing and describing the particular materials and methodologies for which the document was cited.
Although the present invention has been described in connection with preferred embodiments thereof, it will be appreciated by those skilled in the art that additions, deletions, modifications, and substitutions not specifically described may be made without departing from the spirit and scope of the invention. Terminology used herein should not be construed as being “means-plus-function” language unless the term “means” is expressly used in association therewith.
Synthesis of LCNP and PEG-Chol Conjugation onto the Surface
Nag, O. K., et al., Lipid Raft-Mediated Membrane Tethering and Delivery of Hydrophobic Cargos from Liquid Crystal-Based Nanocarriers. Bioconjugate Chem. 2016. 27(4): 982-993.
Nag, O. K., et al., Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier. J. Vis Exp. 2017. (120).
Spillmann, C. M., et al., Multifunctional Liquid Crystal Nanoparticles for Intracellular Fluorescent Imaging and Drug Delivery. ACS Nano, 2014. 8(7): 6986-6997.
Zhou, J. C., et al., Tuning mechanical properties of liquid crystalline nanoparticles. J. Colloid Interface Sci. 2012. 368(1): 152-157.
Spillmann, C. M., et al., Role of Surfactant in the Stability of Liquid Crystal-Based Nanocolloids. Langmuir, 2009. 25(4): 2419-2426.
ZnPC and ZnPC Loaded NPs for PDT
Kim, J., et al., Selective photosensitizer delivery into plasma membrane for effective photodynamic therapy. J. Control Release, 2014. 191: 98-104.
Ping, J.-t., et al., Synthesis and optimization of ZnPc-loaded biocompatible nanoparticles for efficient photodynamic therapy. J. Mater. Chem. B. 2016. 4(25): 4482-4489.
Makhseed, S., et al., Water-soluble non-aggregating zinc phthalocyanine and in vitro studies for photodynamic therapy. Chem. Commun. 2013. 49(95): 11149-11151.
Lucky, S. S., et al., Nanoparticles in photodynamic therapy. Chem. Rev. 2015. 115(4): 1990-2042.
Feuser, P. E., et al., Synthesis of ZnPc loaded poly(methyl methacrylate) nanoparticles via miniemulsion polymerization for photodynamic therapy in leukemic cells. Mater. Sci. Eng. C. 2016. 60: 458-466.
Kiew, L. V., et al., Near-infrared activatable phthalocyanine-poly-L-glutamic acid conjugate: increased cellular uptake and light-dark toxicity ratio toward an effective photodynamic cancer therapy. Nanomedicine, 2017. 13(4): 1447-1458.
Jin, Y, et al., Nanostructures of an amphiphilic zinc phthalocyanine polymer conjugate for photodynamic therapy of psoriasis. Colloids Surf. B. Biointerfaces, 2015. 128: 405-409.
Li, L., et al., Enhanced photodynamic efficacy of zinc phthalocyanine by conjugating to heptalysine. Bioconjugate Chem. 2012. 23(11): 2168-2172.
Drozdek, S., et al., Two-Photon Induced Fluorescence Energy Transfer in Polymeric Nanocapsules Containing CdSexS1-x/ZnS Core/Shell Quantum Dots and Zinc(II) Phthalocyanine. J. Phys. Chem. C. 2016. 120(28): 15460-15470.
This Application claims the benefit of patent application nos. 62/546,778 filed on Aug. 17, 2018 and PCT/US18/00220 filed on Aug. 16, 2018, the entirety of each of which is incorporated herein by reference.
Number | Date | Country | |
---|---|---|---|
62546778 | Aug 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US18/00220 | Aug 2018 | US |
Child | 16793191 | US |